Phase 3 Study of Duvakitug for Moderately to Severely Active Ulcerative Colitis Initiated
A Phase 3 maintenance study is underway to evaluate duvakitug's efficacy and safety in patients with moderately to severely active Ulcerative Colitis.
Asset / Drug
Drug and asset intelligence for Duvakitug with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.